• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

May Issue of Patient Care Online Digital Edition is Now Live

News
Article

Find details on a novel web tool found to help patients determine their eligibility for OTC statin use, FDA clearance of the first AI-based algorithm to detect HF during routine exams, and more.

Patient Care Online Digital Edition May 2024

Patient Care Online Digital Edition May 2024

The latest issue of the Patient Care Online digital edition is now live. The digital edition is available monthly and offer a selection of the website's top ranked news and features, as measured by Patient Care reader interest and engagement.

This month's issue focuses on cardiovascular disease and technology, including findings from a study on the efficacy and safety of a novel web app for over-the-counter statin medication, details on the first FDA-cleared AI-based algorithm to detect heart failure during routine examinations, and details on a remotely delivered-lipid lowering program found to help patients reach target LDL-C levels.

Find out more in the digital edition, here.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report / image credit American Heart Association

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

Grace Halsey
November 11th 2024
Article

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity / image credit Steven J Nicholls, MBBS, PhD, Monash University Melbourne, Australia

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

Grace Halsey
November 5th 2024
Article

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Why Are Women Still Missing from Cardiovascular Clinical Trials? image credit ©Chinnapong/stock.adobe.com

Why Are Women Still Missing from Cardiovascular Clinical Trials?

Hayden E. Klein
October 17th 2024
Article

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

© 2024 MJH Life Sciences

All rights reserved.